Please ensure Javascript is enabled for purposes of website accessibility

Why Impel NeuroPharma Stock Blasted 27% Higher Thursday

By Eric Volkman – Sep 9, 2021 at 6:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A big sell-off in the stock is followed by a sudden bull rush, days after the company wins its first FDA approval.

What happened

After three consecutive days of declines that saw its shares crater from nearly $34 per share to less than half that figure, Impel NeuroPharma (IMPL -3.72%) rocketed more than 27% higher on Thursday. With some recent good news about the company, investors were obviously pouncing on that weakened stock price.

So what

The sell-off in the previous days wasn't necessary warranted, as recent developments for the company have generally been quite favorable. Chief among these was last Friday's announcement that the Food and Drug Administration had approved the company's lead candidate, migraine headache treatment Trudhesa.

A medical professional using a microscope.

Image source: Getty Images.

This is Impel NeuroPharma's first approved medication, and although there is a similar good treatment on the market (Bausch Health's Migranal), it gives the company a badly needed revenue-generating product.

Meanwhile, in the glow of the FDA's approval, Impel NeuroPharma announced a new round of capital raising. After market hours on Tuesday, the biotech said it has commenced a 3-million-share issue of its common stock to the public. It also intends to offer the issue's underwriters up to an additional 450,000 shares.

In the prospectus for the offering, Impel estimated that the price would be $18.65 per share, 12% above Wednesday's close, although a final price has not been fixed.

Now what

Impel NeuroPharma's intentions with this incoming capital seem sensible, so maybe that's another source of the new investor bullishness.

In the prospectus, the company said the monies will be spent for, among other purposes, funding the commercial launch and marketing for Trudhesa, and pushing what is now its leading pipeline drug -- INP105, for acute agitation in bipolar disorder and schizophrenia-- further up the development ladder.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Impel NeuroPharma, Inc. Stock Quote
Impel NeuroPharma, Inc.
$2.59 (-3.72%) $0.10
Bausch Health Companies Stock Quote
Bausch Health Companies
$6.82 (0.89%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.